Fate Therapeutics
12278 Scripps Summit Drive
San Diego
California
92131
United States
Tel: 858.875.1800
Website: http://www.fatetherapeutics.com/
Email: info@fatetherapeutics.com
About Fate Therapeutics
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s effector cell pipeline includes multiplexed-engineered, iPSC-derived natural killer (NK) cell and T-cell product candidates, which incorporate novel synthetic controls of cell function, such as chimeric antigen receptors (CARs) to target tumor-associated antigens and are intended to deliver multiple mechanisms of therapeutic importance to patients including in combination with well-established cancer therapies. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
174 articles about Fate Therapeutics
-
San Diego's Fate Therapeutics Lands a Deal With Star Scientist to Work on Off-the-Shelf T-Cell Immunotherapies
9/8/2016
-
Fate Therapeutics To Present At The 2016 Wedbush PacGrow Healthcare Conference
8/10/2016
-
Fate Therapeutics Reports Second Quarter 2016 Financial Results
8/9/2016
-
Fate Therapeutics Announces Issuance Of U.S. Patent On Compositions Of Human Induced Pluripotent Cells
7/26/2016
-
Fate Therapeutics Announces FDA Fast Track Designation For Protmune
6/20/2016
-
Fate Therapeutics To Host Off-The-Shelf Cancer Immunotherapy Focus Session At 2016 Annual Meeting Of International Society for Stem Cell Research
6/16/2016
-
Fate Therapeutics Appoints Chris M. Storgard, M.D. As Chief Medical Officer
5/17/2016
-
Fate Therapeutics Announces Preclinical Data Highlighting Persistent Effector Function Of Allogeneic Natural Killer Cell Cancer Immunotherapy
5/16/2016
-
Fate Therapeutics Reports First Quarter 2016 Financial Results
5/10/2016
-
Fate Therapeutics To Webcast Conference Call Reporting First Quarter 2016 Financial Results On May 9, 2016
5/3/2016
-
Fate Therapeutics To Present At The Needham & Company 15th Annual Healthcare Conference
4/6/2016
-
Fate Therapeutics To Webcast Conference Call Reporting Fourth Quarter And Full Year 2015 Financial Results On March 3, 2016
2/26/2016
-
Fate Therapeutics To Present Preclinical Data For Protmune At 2016 BMT Tandem Meetings
2/22/2016
-
Fate Therapeutics Announces FDA Clearance Of Investigational New Drug Application For Protmune For Prevention Of Acute Gvhd And CMV Infection
1/27/2016
-
Fate Therapeutics To Present At Biotech Showcase 2016
1/7/2016
-
Fate Therapeutics Discontinues Development of ProHema in Patients Undergoing Cord Blood HCT
12/7/2015
-
Fate Therapeutics To Present At Oppenheimer 26th Annual Healthcare Conference
12/3/2015
-
Fate Therapeutics To Present Strategy For The Development Of Off-The-Shelf Cancer Immunotherapies At American Society of Hematology 2015
11/5/2015
-
Fate Therapeutics To Present Preclinical Data For Protmune At American Society of Hematology 2015 Annual Meeting
11/5/2015
-
Fate Therapeutics Strengthens Intellectual Property Position With New U.S. Patent Covering Induced Pluripotent Cell Compositions
10/28/2015